about
Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexesAggregation of human S100A8 and S100A9 amyloidogenic proteins perturbs proteostasis in a yeast modelTyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity.Observation of sequence specificity in the seeding of protein amyloid fibrils.The interaction of equine lysozyme:oleic acid complexes with lipid membranes suggests a cargo off-loading mechanism.α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade.Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure.Unlocked concanavalin A forms amyloid-like fibrils from coagulation of long-lived "crinkled" intermediates.A generic method for design of oligomer-specific antibodies.Intrinsic determinants of Aβ(12-24) pH-dependent self-assembly revealed by combined computational and experimental studies.Equine lysozyme: the molecular basis of folding, self-assembly and innate amyloid toxicity.Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate.Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity.S100A8/A9 amyloidosis in the ageing prostate: relating ex vivo and in vitro studies.Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation.Abnormal pigment epithelium-derived factor processing in progressive myopia.The misfolded pro-inflammatory protein S100A9 disrupts memory via neurochemical remodelling instigating an Alzheimer's disease-like cognitive deficit.Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid?Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence.A complex of equine lysozyme and oleic acid with bactericidal activity against Streptococcus pneumoniae.Expression and purification of active recombinant equine lysozyme in Escherichia coli.S100A9 Protein Aggregates Boost Hippocampal Glutamate Modifying Monoaminergic Neurochemistry: A Glutamate Antibody Sensitive Outcome on Alzheimer-like Memory Decline.Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants.Fibrillation of carrier protein albebetin and its biologically active constructs. Multiple oligomeric intermediates and pathways.Observation of the Early Structural Changes Leading to the Formation of Protein Superstructures.Finke-Watzky Two-Step Nucleation-Autocatalysis Model of S100A9 Amyloid Formation: Protein Misfolding as "Nucleation" Event.Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine.Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants.The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms.Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.Antibodies to Glutamate Reversed the Amnesic Effects of Proinflammatory S100A9 Protein Fibrils in Aged C57Bl/6 Mice.Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease.Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters.Amyloid β-peptides 1-40 and 1-42 form oligomers with mixed β-sheets.Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimer's DiseaseIndependent Nucleation and Heterogeneous Assembly of Structure During Folding of Equine Lysozyme
P50
Q24312111-A53D0017-7F23-41ED-9DA5-C50113927E64Q28487681-39F94093-D4E2-4466-85FE-6F6C76A25B18Q30832756-985A65D1-2231-4E04-8ECD-AEEB17162E71Q33204175-83D7563E-65EA-42E9-8A26-B30651CFEB82Q33540518-53363012-5803-4EFD-96C8-3DB011CF321AQ33889446-16DA7211-65C6-4F35-AC20-EDF6E75D9CE0Q34104401-5DA4E550-36DE-4C30-B4DE-5E1192CB1EFEQ34322134-34644863-6FF4-4804-8FC6-89B07EF40140Q34851754-1F193F65-F94A-4105-97AB-2A77817B9154Q35117526-6489BB98-614E-49A2-8CEA-0F200CD41AC8Q35225705-7480E440-E64C-4FE1-80F8-2A48E4A7DCA2Q36833026-9252A5D0-EC26-4DC0-95C4-46C0543AE140Q37182479-52537E59-7F3E-40A6-BB5D-1B8B225BC995Q37803273-766D4191-2C9B-4546-87BD-7DA84C5BC233Q38004968-9AACE0FB-222E-4B3E-9ECD-1C03DF612EDCQ38927111-BEBD1719-8BD6-4BF2-ABFF-312987593865Q39257498-4EA105FA-151C-4C46-A684-49D4F1BDD1E1Q39426687-89782967-2A65-4247-8DA2-54A5CDFE5BFEQ39930449-6655BF05-E857-4FBC-9251-0E531D1AD474Q40274131-E9B2FE78-7F01-414E-8212-09F331D97AA8Q40299317-3DE71321-DD2A-4013-8788-29BC576B6E69Q41820519-4A768AE6-18E0-443A-91ED-7930E24E4724Q43299342-E64C3FE5-ECB8-46FE-9C57-9AEDC69AB723Q46257159-EBF59A3E-6C9F-4462-8336-4DDBF08012BAQ46492867-9482D703-9978-488D-B9CD-9A1FC627C50CQ46510187-E83C3EE9-8008-41B2-BF37-C8B24F1F3BD4Q46684049-FC14549A-A248-44EA-8746-32784585D17AQ47827529-B8DF5533-DB33-472D-9545-F8050078B765Q48202370-FE3D7DDB-D480-467E-9D07-A449B8DBEA55Q48241119-9A7C2B4B-7B79-43AF-94E1-881C7B1B9500Q48375752-0B5970C4-718D-4A9B-907F-C9FD42A9DB57Q48437595-D3BD85A8-A211-45A6-B159-A0DD39201BB7Q48567933-3D810C25-B8E6-4BD7-8B06-B01554893CB9Q50453861-0693BFC0-4338-4CD9-BB1B-C2F2D1863E61Q50777223-8A75E055-3519-4516-B74D-697FFAD87F7BQ53286638-0BE95AA6-3385-497B-9C61-8BBCAA01D7B0Q54959267-5EB13067-F416-4DFE-8992-77FCB3AA6C08Q55472821-82E00D93-C086-4D70-BA8E-21500511C9F7Q57777508-6EC2D87C-D149-43FC-8893-431A591283E1Q57908602-B4553F2B-387A-4B6E-AED9-9906FCC8F5E8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ludmilla A Morozova-Roche
@ast
Ludmilla A Morozova-Roche
@es
Ludmilla A Morozova-Roche
@nl
Ludmilla Morozova-Roche
@de
Ludmilla Morozova-Roche
@en
type
label
Ludmilla A Morozova-Roche
@ast
Ludmilla A Morozova-Roche
@es
Ludmilla A Morozova-Roche
@nl
Ludmilla Morozova-Roche
@de
Ludmilla Morozova-Roche
@en
altLabel
Ludmilla A. Morozova-Roche
@en
prefLabel
Ludmilla A Morozova-Roche
@ast
Ludmilla A Morozova-Roche
@es
Ludmilla A Morozova-Roche
@nl
Ludmilla Morozova-Roche
@de
Ludmilla Morozova-Roche
@en
P106
P108
P21
P31
P496
0000-0001-5886-2023